Efficacy
Sandostatin® LAR Depot (octreotide acetate) for injectable suspension for treatment of the severe diarrhea and flushing associated with metastatic carcinoid tumors
Control you can trust
For the severe diarrhea and flushing associated with metastatic carcinoid tumors.1
DELIVER CONTROL WITH SANDOSTATIN LAR DEPOT
Reduction in Severe Diarrhea
REDUCTION IN SEVERE DIARRHEA THROUGH WEEK 241,2
Reduction in Flushing
REDUCTION IN FLUSHING EPISODES THROUGH WEEK 241,2
HIGHLIGHTS OF IMPORTANT SAFETY INFORMATION
Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of cholelithiasis (gallstones) resulting in complications; glucose metabolism; thyroid and cardiac function; and nutritional absorption (periodic monitoring is recommended). Cardiac function: use with caution in at-risk patients.
Please see study design details below.
Reduction in 5-HIAA
REDUCTION IN 5-HIAA LEVELS THROUGH WEEK 241,2
5-HIAA, 5-hydroxyindoleacetic acid.
a5-HIAA reductions are within the range reported in published literature for patients treated with octreotide (10%-50%).
LEARN MORE ABOUT THE IMPORTANCE OF 5-HIAA
5-HIAA is a critical marker of carcinoid syndrome.3,4,7 Learn more about 5-HIAA testing and why suppressing 5-HIAA levels is important.
Download 5-HIAA PDF
Study Design
A 6-month clinical trial of malignant carcinoid syndrome was performed in patients who had previously been shown to be responsive to Sandostatin® (octreotide acetate) Immediate-Release Injection. Patients received 10-mg, 20-mg, or 30-mg doses of Sandostatin LAR Depot every 28 days or continued their Sandostatin Immediate-Release Injection regimen. Patients receiving Sandostatin LAR Depot who experienced symptom flare-ups were permitted to use supplemental Sandostatin Immediate-Release Injection until symptoms were again controlled to screening frequency.1,2